StockNews.AISignal intelligence
AVITA Medical, Inc. · NASDAQ · Healthcare
Browse public RCEL signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Avita Medical revised revenue guidance for Q4 and 2024 downwards. Projected Q4 revenue is $18.4 million, below earlier estimates. 2024 revenue expected at $64.3 million, missing prior forecasts. Inventory adjustments delayed purchasing, affecting near-term sales. Despite challenges, Avita plans growth with new product launches.
View signal analysisRCEL shares dropped sharply after cutting fourth-quarter revenue guidance. AVITA Medical's delay of GAAP profitability impacted investor sentiment negatively. The stock fell 21.1% to $11.10 in pre-market trading.
View signal analysisAVITA Medical's shares dropped 19% after reducing profit forecasts again. Regenerative medicine firm delayed profitability targets, affecting investor confidence.
View signal analysis